TOKYO - Shionogi, set on global expansion, has rejected initial plans to expand into Europe, instead turning to emerging markets in Asia
Continue reading "Shionogi Spurns Europe, Places Bets On Asia For Global Expansion - Bio Expo Japan" »
Teruo Yasufuku, managing director for Astellas Pharma India, is soft-spoken and carefully measures every answer that he shares with the media. But the law graduate who started his career as a medical representative with Fujisawa in 1983 has been recognized for his leadership skills and the enthusiasm to be the best in the business.
Continue reading "Indian Companies Are Becoming More Creative, Says Astellas India Managing Director Teruo Yasufuku: An Interview With PharmAsia News" »
Endo's pending acquisition of HealthTronics and its settlement with Impax and Sandoz over generic Opana ER removes some near-term pressure on its shares.
read more
Continue reading "Latest News from "The Pink Sheet" DAILY - Endo Explains HealthTronics Acquisition to Wall Street" »
In this
complimentary report, PharmAsia News takes a closer look at R&D strategies in Asia, focusing on India, China and Korea. In India, Sanofi-Aventis's media-shy leader Shailesh Ayyangar sits down with PharmAsia News in a rare interview to discuss Sanofi's strategy in rural markets.
Continue reading "Will Sanofi-Aventis Succeed In India With Its Rural Strategy?" »
MUMBAI - Marketing of patented and branded drugs is a relatively new concept in India but going by the initial strategies put into play by multinational companies - most notably for the DPP-4 inhibitors Januvia (sitagliptin), Galvus (vildagliptin) and Onglyza (saxagliptin) - it has all the ingredients of blowing up into an all out war in the race to capture the mind recall of doctors.
Continue reading "Big Brand Fights Come To India As Januvia, Galvus And Onglyza Vie For Market Share" »
Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.
Continue reading "The Rise Of Japanese Pharma Dealmakers" »
Agency needs to better define the evidence threshold for reporting suspected clinical trial fraud to the agency, industry commenters say.
read more
Continue reading "Latest News from "The Pink Sheet" DAILY - Genzyme, Pfizer and Abbott News" »